BioNxt Solutions Inc. — Investor Relations & Filings
BioNxt Solutions Inc. is a clinical-stage bioscience company focused on developing next-generation drug formulations and advanced delivery systems. The company specializes in high-performance solutions, including sublingual thin films and transdermal patches, designed to enhance bioavailability and patient compliance across critical therapeutic areas. BioNxt's R&D pipeline targets neurology, immunology, oncology, and mental health. Core platforms include advanced drug delivery systems for chronic diseases, a targeted chemotherapy platform designed to reduce systemic toxicity by delivering cytotoxic agents directly to tumors, and a proprietary library of engineered psychedelic compounds for neurological and psychiatric conditions. The company also develops diagnostic screening tests and active pharmaceutical ingredients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Report of exempt distribution excluding schedule 1 of Form 5.pdf | 2022-12-15 | English | |
| News release - English.pdf | 2022-11-30 | English | |
| Material change report - English.pdf | 2022-11-14 | English | |
| Other securityholders documents - English.pdf | 2022-11-14 | English | |
| News release - English.pdf | 2022-11-10 | English | |
| News release - English.pdf | 2022-10-11 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2022
15 filings
| |||||
| 26537698 | Report of exempt distribution excluding schedule 1 of Form 5.pdf | 2022-12-15 | English | ||
| 13630963 | News release - English.pdf | 2022-11-30 | English | ||
| 26237327 | Material change report - English.pdf | 2022-11-14 | English | ||
| 26237432 | Other securityholders documents - English.pdf | 2022-11-14 | English | ||
| 26203593 | News release - English.pdf | 2022-11-10 | English | ||
| 13619871 | News release - English.pdf | 2022-10-11 | English | ||
| 25875970 | News release - English.pdf | 2022-10-06 | English | ||
| 13617001 | News release - English.pdf | 2022-09-20 | English | ||
| 25721179 | Management information circular - English.pdf | 2022-09-16 | English | ||
| 25721178 | Notice of meeting - English.pdf | 2022-09-16 | English | ||
| 25721177 | Form of proxy - English.pdf | 2022-09-16 | English | ||
| 25721176 | Other.pdf | 2022-09-16 | English | ||
| 25632542 | Material change report - English.pdf | 2022-09-02 | English | ||
| 25632322 | Material change report - English.pdf | 2022-09-02 | English | ||
| 25632372 | News release - English.pdf | 2022-09-02 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
BioNxt Solutions Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/47545/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=47545 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=47545 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=47545 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 47545}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for BioNxt Solutions Inc. (id: 47545)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.